Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Psoriasis Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of California, San Francisco

San Francisco, California, 94158, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days)

Exclusion criteria

None

Treatment and study plan

In situ cutaneous microdevice

Device

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.

Triamcinolone

Drug

Triamcinolone

5-fluorouracil

Drug

5-fluorouracil

Calcipotriene

Drug

Calcipotriene

Tapinarof

Drug

Tapinarof

Crisaborole

Drug

Crisaborole

Tacrolimus

Drug

Tacrolimus

Adalimumab

Drug

Adalimumab

etanercept

Drug

Etanercept

Certolizumab

Drug

Certolizumab

Infliximab

Drug

Infliximab

secukinumab

Drug

Secukinumab

Ixekizumab

Drug

Ixekizumab

Apremilast

Drug

Apremilast

Risankizumab

Drug

Risankizumab

Ustekinumab

Drug

Ustekinumab

Hydroxychloroquine

Drug

Hydroxychloroquine

methotrexate

Drug

Methotrexate

Mycophenolate

Drug

Mycophenolate

azathioprine

Drug

Azathioprine

Chloroquine

Drug

Chloroquine

cyclosporine

Drug

Cyclosporine

tofacitinib

Drug

Tofacitinib

Deucravacitinib

Drug

Deucravacitinib

Dupilumab

Drug

Dupilumab

Tralokinumab

Drug

Tralokinumab

Guselkumab

Drug

Guselkumab

Tildrakizumab

Drug

Tildrakizumab

Baractinib

Drug

Baractinib

Abrocitinib

Drug

Abrocitinib

Upadacitinib

Drug

Upadacitinib

Lebrikizumab

Drug

Lebrikizumab

Nemolizumab

Drug

Nemolizumab

Ruxolitinib

Drug

Ruxolitinib

Bimekizumab

Drug

Bimekizumab

Roflumilast

Drug

Roflumilast

Primary outcomes

  1. Number of participants with adverse events

    Time frame: 1 year

    The safety of microdevice placement and removal will be based on assessment of adverse events.

  2. Proportion of retrieved devices with assessable tissue

    Time frame: 1 year

    The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.

Secondary outcomes

  1. Change in local skin inflammation (molecular assays)

    Time frame: 1 year

    Feasibility of utilizing quantitative histopathologic assessment and/or transcriptional profiling to determine whether there is local change in lesional rash-affected skin with clinically relevant skin inflammation treating agents.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeffrey Cheng, MD, PhD

CONTACT

[email protected]

415-575-0524

Raymond Cho, MD, PhD

CONTACT

[email protected]

415-353-7800

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

Utilization of a Cutaneous Therapy In Situ Microdevice

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jan 20, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.